The regulation of CD4+ T cell immune responses toward Th2 cell development by prostaglandin E2

2011 ◽  
Vol 11 (10) ◽  
pp. 1599-1605 ◽  
Author(s):  
Yu-Shi Bao ◽  
Ping Zhang ◽  
Ru-Juan Xie ◽  
Mei Wang ◽  
Zhi-Yong Wang ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Prostaglandin E2 ◽  
Cell Development ◽  
Cd4 T Cell ◽  
Th2 Cell ◽  
T Cell Immune Responses

scholarly journals NKT Cell-Dependent Regulation of Secondary Antigen-Specific, Conventional CD4+ T Cell Immune Responses

2010 ◽  
Vol 184 (10) ◽  
pp. 5589-5594 ◽  
Author(s):  
YoungHyun Shin ◽  
Changwan Hong ◽  
Hyunji Lee ◽  
Jung Hoon Shin ◽  
Seokmann Hong ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Cd4 T Cell ◽  
Nkt Cell ◽  
T Cell Immune Responses

scholarly journals Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4+ T-cell development during rheumatoid arthritis

2018 ◽  
Vol 67 (7) ◽  
pp. 589-596 ◽  
Author(s):  
Janaiya S. Samuels ◽  
Lauren Holland ◽  
María López ◽  
Keya Meyers ◽  
William G. Cumbie ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
T Cell ◽  
Prostaglandin E2 ◽  
T Cell Development ◽  
Cell Development ◽  
Cd4 T Cell

scholarly journals Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort

2014 ◽  
Vol 162 (2) ◽  
pp. 264-272 ◽  
Author(s):  
Rose Nabatanzi ◽  
Lois Bayigga ◽  
Isaac Ssinabulya ◽  
Agnes Kiragga ◽  
Andrew Kambugu ◽  
...  
Keyword(s):  
T Cell ◽  
Antiretroviral Therapy ◽  
Immune Responses ◽  
Cd4 T Cell ◽  
Cd4 Counts ◽  
T Cell Immune Responses

scholarly journals Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1757-1757
Author(s):  
Kalpana Parvathaneni ◽  
Kyabeth Toress-Rodriguez ◽  
Wenzhao Meng ◽  
James Knox ◽  
Xiaoming Xu ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Board Of Directors ◽  
T Cell Activation ◽  
Research Funding ◽  
Cell Activation ◽  
Cd4 T Cell ◽  
Advisory Committees ◽  
Cell Immunity ◽  
T Cell Immune Responses

Abstract Abstract Background: The two FDA approved mRNA-based SARS-CoV2 vaccines have shown >90% efficacy at preventing COVID and eliciting protective immunity in nearly all healthy individuals. However, the extent of vaccine induced antibody and T cell immunity in immunocompromised patients is not well known. Our study objective is to determine if patients with hematologic malignancies treated with B-cell targeting chimeric antigen receptor (CAR) T cell therapies can mount antibody and T cell immune responses to SARS-CoV2 vaccines. A prospective single-center study to evaluate the SARS-CoV2 immune responses in immunocompromised individuals (COVAX Study) was initiated at University of Pennsylvania following the IRB guidelines. The study enrolled 8 healthy adults,12 patients are in remission after treatment (average of 40.6 months) with CART cells targeting either CD19 or CD19+CD22 and received both doses of SARS-CoV2 vaccine. Methods and Results: Serology to SARS-CoV2 spike-receptor binding domain (RBD) IgG, RBD-IgA, RBD-IgM and spike-specific T cell responses were measured prior to vaccination and serially up to 28 days after booster vaccination. RBD-IgG and RBD-IgA were detected in 8/8 and 7/8 healthy subjects compared to 5/12 and 2/12 CART patients, respectively (Figure A). In the CART cohort, several patients who demonstrated an induction of RBD-IgG (57.2/uL +/- 20.2) compared to those who were RBD-IgG-negative (9/uL +/- 10.1, ANOVA with multiple comparisons test p=0.017) have higher level of circulating B cells. No association was found with time since CART infusion, age, disease type, or vaccine manufacturer. All 8 healthy subjects demonstrated induction of SARS-Cov2 spike-specific CD4 + T cell immunity compared to 7 out of 11 CART patients (Figure B). RBD-IgG responses were not correlated with CD4 + T cell activation (Pearson correlation, R=0.21, p=0.53). Indeed, 3 CART patients demonstrated robust CD4 + T cell activation despite absence of antibody induction. Overall, 8/12 CART patients demonstrated induction of either or both humoral and T cell immune responses. Conclusions: We show that immune responses to SARS-CoV2 mRNA vaccines are induced in majority of patients who have been treated with CART therapies targeting B-cell lineage antigens. Induction of vaccine-specific antibody was strongly associated with the level of circulating B cells. However, in CART cohort patients despite severe humoral immune deficiency, strong CD4 + T cell responses were observed suggestive of a sufficient protective immunity. Figure 1 Figure 1. Disclosures Frey: Novartis: Research Funding; Sana Biotechnology: Consultancy; Kite Pharma: Consultancy; Syndax Pharmaceuticals: Consultancy. Garfall: Amgen: Honoraria; CRISPR Therapeutics: Research Funding; GlaxoSmithKline: Honoraria; Janssen: Honoraria, Research Funding; Novartis: Research Funding; Tmunity: Research Funding. Porter: American Society for Transplantation and Cellular Therapy: Honoraria; Genentech: Current equity holder in publicly-traded company, Ended employment in the past 24 months; ASH: Membership on an entity's Board of Directors or advisory committees; DeCart: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; National Marrow Donor Program: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Tmunity: Patents & Royalties; Wiley and Sons Publishing: Honoraria. June: AC Immune, DeCART, BluesphereBio, Carisma, Cellares, Celldex, Cabaletta, Poseida, Verismo, Ziopharm: Consultancy; Tmunity, DeCART, BluesphereBio, Carisma, Cellares, Celldex, Cabaletta, Poseida, Verismo, Ziopharm: Current equity holder in publicly-traded company; Novartis: Patents & Royalties.

Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

2009 ◽  
Vol 9 (13-14) ◽  
pp. 1530-1539 ◽  
Author(s):  
Jae Yeo Park ◽  
Min Ja Jang ◽  
Yoon Hee Chung ◽  
Kyung Yong Kim ◽  
Sung Su Kim ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Cd40 Ligand ◽  
Cd4 T Cell ◽  
T Cell Immune Responses

scholarly journals CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2

2011 ◽  
Vol 108 (46) ◽  
pp. 18778-18783 ◽  
Author(s):  
L. Chen ◽  
Y. Zhu ◽  
G. Zhang ◽  
C. Gao ◽  
W. Zhong ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Prostaglandin E2 ◽  
T Cell Immune Responses
Sign in / Sign up

Export Citation Format

Share Document